# Adversarial review log — lipid-heart-diet

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.
Round 2 of the Sol 6.1 adversarial review programme (group 3).

| Item | Value |
|---|---|
| Level before → after | Ε (Context-specific causality established) → Ε (unchanged) |
| Confidence before → after | Moderate → Moderate (unchanged) |
| Role / Momentum / Stability / Divergence | unchanged (reinforcing / stabilizing factor; Mechanistic only; Stable; Contested) |
| Findings | Critical 0, Major 0, Minor 2, Editorial 0 |
| PMIDs verified | 53/53 reference PMIDs resolved to the stated title, first author, journal and year; no retractions or expressions of concern; five linked errata correctly attached to parent sources |
| Load-bearing claims spot-checked | 12 |
| Validator | PASS — 0 fail, 0 warn, 31 pass (validate_review.py v2.3, the batch's own copy). Output in `validator.txt`; pre-review report kept at `sol61-original/validation-report.json` |

## Findings

| ID | Severity | Location | Original → corrected | Evidence |
|---|---|---|---|---|
| LHD-1 | Minor | Registered claim and scope, Selection line | "; existing HIV draft consulted after a source-based checkpoint" removed | No HIV draft belongs to this case's provenance; the sentence is batch boilerplate present in all five cases and accurate only for `hiv-aids`. |
| LHD-2 | Minor | REFERENCES entry 4 | "DOI: ." → "No DOI in the PubMed record." | Known empty-field rendering defect; PubMed carries no DOI for PMID 3773141. |

## Rejected findings (checked, no change)

1. Headline Ε. Ζ is blocked because no long-term isoenergetic saturated-for-cis-unsaturated trial with verified apoB separation and adjudicated events exists and the historical replacement trials conflict; Γ would wrongly reimpose the biomarker cap on a set containing randomized particle-lowering outcome trials and human genetics. Cap precedence ("a universal cap governs the inference from that system to the hypothesis's claimed scope") supports Η for the SC2 component with Ε for the diet-specific SC3.
2. Confidence Moderate — defensible here: the diet-specific clinical literature is heterogeneous in direction and comparator, matching the Moderate band rather than "reproducibility well-established". (The identical access-based rationale recurs across the batch; flagged for the lead, corrected only in `hiv-aids`, where the High band is plainly met.)
3. Momentum "Mechanistic only" names its artifacts (RISSCI-2 PMID 42664559; VESALIUS-CV PMID 41211925).
4. Divergence "Contested" — the field framing genuinely splits, so no single implied level applies.
5. Primary-subclaim aggregation on SC3 → Ε; alternatives reported (weakest-link Γ, scope-matched Ε).
6. Minnesota and Sydney retained as opposing evidence, not dismissed as proven trans-fat contamination, and their embedded systematic reviews excluded from the primary count — both correct.
7. Numeric and design claims verified: PMIDs 26016869 (null primary FMD; LDL −11.3%/−13.6%; projected, not observed, 17–20% mortality reduction), 39111551 (nonrandomized sequential; LDL response −1.39 to +0.77 mmol/L), 42664559 (responder-selected; absorption does not explain), 27071971 (−13.8% vs −1.0% cholesterol, no mortality benefit), 23386268 (458 men, secondary prevention), 29511019 (butter vs coconut +0.42, vs olive +0.38 mmol/L), 41211925 (3-point MACE HR 0.75, n=12,257, 93% White), 29897866, 31227804.

## Residual limitations

- Access depth unchanged: 4 partial-body and 49 abstract/status examinations.
- Five linked errata recorded but unexamined.
- Rubric routing to 06-metabolism-aging for an ASCVD nutrition claim remains an explicit adaptation, flagged in the review itself.
- The boilerplate corrected in LHD-1 is still present in the three sibling cases of this batch that are outside this assignment (`telomere-shortening`, `inflammation-depression`, and — correctly — `hiv-aids`).

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.